Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may ...

Children with asthma experienced fewer exacerbations and better control with dupilumab regardless of the duration of their ...

The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater ...

All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of ...

The poster presentations will be available on Connect’s website under the Presentations and Publications section.

A new study published in the Journal of the European Academy of Dermatology and Venerology found dupilumab to have a ...

Dupilumab shows significant efficacy in reducing itch and hives in CSU patients unresponsive to antihistamines. The CUPID A and CUPID C trials reported a two-thirds reduction in itch and urticaria ...

Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval from the US Food and Drug Administration (FDA) for treating chronic spontaneous urticaria (CSU ...

FDA approves Dupixent as the first new CSU treatment in over a decade. 2. Phase 3 trial shows significant symptom reduction ...

The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by ...

Dupilumab is prescribed for the treatment of moderate-to-severe atopic dermatitis (a skin disorder in which the skin is dry and itchy with red and scaly rashes) in adult patients who do not ...

These medications include benralizumab and dupilumab injections. Emphysema is a type of chronic obstructive pulmonary disease (COPD) that occurs when the air sacs in the lungs lose elasticity or ...